DNA (alkylation), delivered via aminopeptidase-mediated intracellular

Class

Small molecule (lipophilic peptide-alkylator conjugate / peptidase-potentiated alkylating agent)

Pathway

Rapidly enters cells and is hydrolyzed intracellularly by aminopeptidases (e.g. ANPEP), which are upregulated in myeloma cells, releasing free melphalan to alkylate DNA and trigger apoptosis

Notes

original target text: DNA (alkylation), delivered via aminopeptidase-mediated intracellular activation

This mechanism centers on DNA alkylation, a chemical modification in which reactive groups form covalent bonds with DNA bases, distorting the double helix and ultimately triggering programmed cell death. Alkylating agents are among the oldest classes of anticancer therapy, valued because rapidly dividing cells are particularly vulnerable to DNA damage they cannot repair before division. The molecule described here is engineered as a lipophilic peptide conjugate that diffuses efficiently into cells, where it is cleaved by aminopeptidases, enzymes that cut peptide bonds and are often overexpressed on the surface of malignant plasma cells found in multiple myeloma. This cleavage releases a well-characterized alkylating agent (melphalan) directly inside the cell. The rationale for this design is to concentrate the active drug preferentially within cells that display high aminopeptidase activity, potentially improving the ratio of tumor cell killing to exposure in normal tissue compared with administering the alkylator in its free form. This approach broadly matters in hematologic malignancies such as multiple myeloma, where durable control depends on inducing cytotoxicity in malignant plasma cells while managing the inherent toxicity of DNA-damaging agents to healthy proliferating tissues, particularly bone marrow.